A Bourson
Overview
Explore the profile of A Bourson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
625
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kunz I, Meier M, Bourson A, Fisseha M, Schilling W
Int J Obes (Lond)
. 2008 Feb;
32(5):863-70.
PMID: 18253160
Objective: To determine the effect of rimonabant on energy expenditure (O2 consumption) in rats at different metabolic states and in cannabinoid CB1 receptor-deficient (CB1R-/-) mice. Design: Animals were exposed to...
2.
Rover S, Adams D, Benardeau A, Bentley J, Bickerdike M, Bourson A, et al.
Bioorg Med Chem Lett
. 2005 Jun;
15(15):3604-8.
PMID: 15975787
Synthesis and evaluation of the activity of new 4-methyl-1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles as 5-HT(2C) receptor agonists are described. Appropriately substituted, several analogs displayed selectivity against the other 5-HT(2) receptor subtypes of 1 order...
3.
Gill R, Alanine A, Bourson A, Buttelmann B, Fischer G, Heitz M, et al.
J Pharmacol Exp Ther
. 2002 Aug;
302(3):940-8.
PMID: 12183650
Ro 63-1908, 1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol, is a novel subtype-selective N-methyl-D-aspartate (NMDA) antagonist that has been characterized in vitro and in vivo. Ro 63-1908 inhibited [(3)H]dizocilpine ((3)H-MK-801) binding in a biphasic manner with...
4.
Pinard E, Alanine A, Bourson A, Buttelmann B, Gill R, Heitz M, et al.
Bioorg Med Chem Lett
. 2001 Aug;
11(16):2173-6.
PMID: 11514163
Starting from Ro-25-6981 as a lead compound, highly potent and selective NR1/2B subtype selective NMDA receptor antagonists, with low activity at alpha(1) adrenergic receptors were developed.
5.
Bentley J, Bourson A, Boess F, Fone K, Marsden C, Petit N, et al.
Br J Pharmacol
. 1999 May;
126(7):1537-42.
PMID: 10323584
1. The present study examined the effects of the selective 5-HT6 receptor antagonist 4-amino-N-(2, 6 bis-methylamino-pyrimidin-4-yl)-benzene sulphonamide (Ro 04-6790) on locomotor activity and unconditioned behaviour in male Sprague Dawley rats...
6.
Boess F, Monsma Jr F, Bourson A, Zwingelstein C, Sleight A
Ann N Y Acad Sci
. 1999 Feb;
861:242-3.
PMID: 9928266
No abstract available.
7.
Sleight A, Boess F, Bos M, Bourson A
Ann N Y Acad Sci
. 1999 Feb;
861:91-6.
PMID: 9928244
Until recently, the majority of actions of the neurotransmitter 5-hydroxytryptamine (5-HT) were generally believed to be mediated by members of the 5-HT1, 5-HT2, 5-HT3 and 5-HT4 receptor families. The application...
8.
Bourson A, Boess F, Bos M, Sleight A
Br J Pharmacol
. 1999 Jan;
125(7):1562-6.
PMID: 9884085
4-Amino-N-(2,4 bis-methylamino-pyrimidin-4-yl) benzene sulphonamide (Ro 04-6790) is a potent, selective and competitive antagonist for the 5-HT6 receptor which can be detected in the cerebro-spinal fluid (CSF) of rats following intraperitoneal...
9.
Boess F, Riemer C, Bos M, Bentley J, Bourson A, Sleight A
Mol Pharmacol
. 1998 Sep;
54(3):577-83.
PMID: 9730917
Ro 63-0563 [4-amino-N-(2,6 bis-methylamino-pyridin-4-yl)-benzene sulfonamide] is a high affinity 5-hydroxytryptamine6 (HT6) receptor antagonist with more than 100-fold selectivity for the 5-HT6 receptor compared with 69 other receptors and binding sites....
10.
Sleight A, Boess F, Bos M, Levet-Trafit B, Riemer C, Bourson A
Br J Pharmacol
. 1998 Jul;
124(3):556-62.
PMID: 9647481
1. This study describes the in vitro characterization of two potent and selective 5-HT6 receptor antagonists at the rat and human recombinant 5-HT6 receptor. 2. In binding assays with [3H]-LSD,...